Hoof Hoof Wall Gets Too Long It Cracks If They’Re on Hard, Dry Will Bend, Then Crack,” Says Ground
Total Page:16
File Type:pdf, Size:1020Kb
GENE THERAPY FOR LAMINITIS? THE BEST WAY TO TREAT SAND COLIC THE HORSE OWNER’S RESOURCE MARCH 2017 ISSUE 474 NOT HORSE A practical approach to HOOF CRACKS STEP-BY-STEP SCRATCHES TREATMENT How orses Visit EQUUSmagazine.com Think *Only at participating retailers. ©2016 Cargill, Incorporated. All Rights Reserved. THE equus HORSE OWNER’S RESOURCE ISSUE 474 MARCH 2017 26 40 DEPARTMENTS FEATURES RESEARCH & MORE 8 LETTERS 26 A field guide to hoof cracks 10 MEDICAL FRONT 14 HANDS ON When a defect appears in the wall • Gene therapy for laminitis? • Slow to shed? of a horse’s hoof, it’s important to be • How horses ask for help • Head off hay shortages able to distinguish a cosmetic flaw • The best way to treat sand colic • Uses for ultrasound from a serious problem. • A question about anesthesia • Shedding tools precautions 24 TACK & GEAR 40 How not to buy a horse 18 FIRST RESPONSE Spring flings Even though I am an experienced Scratches: Pasterns often 67 EQUUS CONSULTANTS horse owner, I was taken in by become crusty and scabby when Riding an older horse a savvy seller. Here’s how I’ll “mud season” turns paddocks protect myself in the future---and 69 STOCK & TRADE into soupy messes. But left you can, too. 71 ADVERTISERS’ untreated, a simple case of PRODUCT GUIDE scratches can escalate into a 51 In search of the painful, chronic condition. 71 GLOSSARY Cuban Paso Fino Words followed by this After 20 years of chasing scant 20 CASE REPORT symbol 0 are defined here evidence, a determined woman A tale of two mandibles: Two 72 BACK PAGE fi nally gains access to one of Cuba’s incidents on the same farm Take a friend to the barn best-kept secrets. illustrate how well horses can recover from jaw injuries, even when the causes and treatments 59 How horses think are very different. In their new book, Francesco De Giorgio and José De Georgio- 64 TRUE TALE Schoorl explain the elements of My golden mare: Before I rescued equine cognition and explore her, Canela had a diffi cult life, but how they shape our relationships love and patience helped her to 20 with horses. learn to trust me. COVER PHOTO BY KATYA DRUZ/ARND BRONKHORST PHOTOGRAPHY equus EDITOR AND ASSOCIATE PUBLISHER Laurie Prinz SENIOR EDITORS Christine Barakat; Laurie Bonner CONTRIBUTING EDITORS Deb Bennett, PhD; Laura Hillenbrand CONTRIBUTING WRITERS Eliza R.L. McGraw; Tom Moates ART DIRECTOR Celia Strain MEDICAL EDITOR Joe Bertone, DVM, MS, DACVIM EDITORIAL ADVISORY BOARD Bradford Bentz, VMD; Jerry Black, DVM; Doug Butler, PhD; Hilary Clayton, BVMS, PhD, MRCVS; Harold Hintz, PhD; Dan Marks, VMD; Ed Robinson, PhD, MRCVS; Stephen Soule, VMD; Peter Timoney, MVB, PhD, FRCVS; Tracy Turner, DVM; Julia H. Wilson, DVM American Horse Publications Official Sponsor, Member Member Kentucky Horse Park AAEP The AAEP does not endorse editorial or Media advertising content unless so acknowledged Partner within the individual article or advertisement. EDITORIAL INQUIRIES (301) 977-3900; fax (301) 990-9015 [email protected] WEBSITE EquusMagazine.com SUBSCRIPTION INQUIRIES P.O. Box 420235, Palm Coast, FL 32142 (800) 829-5910 (U.S. and Canada) or (386) 447-6332; [email protected] To sell copies of EQUUS in your store, contact Wendy Allen, Retail Vision 802-382-6028, email: [email protected] For EQUUS back issues: (800) 829-5910 EXECUTIVE CHAIRMAN Efrem Zimbalist lll CHIEF EXECUTIVE OFFICER & PRESIDENT Andrew W. Clurman SENIOR VICE PRESIDENT, TREASURER & CFO Michael Henry EXECUTIVE VICE PRESIDENT OF OPERATIONS Patricia B. Fox VICE PRESIDENT, CONTROLLER Joseph Cohen VICE PRESIDENT, GROUP PUBLISHER David Andrick VICE PRESIDENT, RESEARCH Kristy Kaus VICE PRESIDENT, INFORMATION TECHNOLOGY Nelson Saenz SENIOR VICE PRESIDENT, DIGITAL & DATA Jonathan Dorn Copyright ©Cruz Bay Publishing, Inc 4 EqUUS 474 march 2017 OSPHOS® (clodronate injection) Bisphosphonate For use in horses only. Brief Summary (For Full Prescribing Information, see package insert) CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: Clodronate disodium is a non-amino, chloro- containing bisphosphonate. Chemically, clodronate disodium is (dichloromethylene) diphosphonic acid disodium salt and is manufactured from the tetrahydrate form. INDICATION: For the control of clinical signs associated with navicular syndrome in horses. CONTRAINDICATIONS: Horses with hypersensitivity to clodronate disodium should not receive OSPHOS. WARNINGS: Do not use in horses intended for human consumption. HUMAN WARNINGS: Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of acci- dental human exposure. PRECAUTIONS: As a class, bisphosphonates may be associ- ated with gastrointestinal and renal toxicity. Sensitivity to drug associated adverse reactions varies with the individual patient. Renal and gastrointestinal adverse reactions may be associated with plasma concentrations of the drug. Bisphosphonates are excreted by the kidney; therefore, conditions causing renal im- pairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions. Concurrent administration of other potentially nephrotoxic drugs should be approached with caution and renal function should be mon- itored. Use of bisphosphonates in patients with conditions or diseases affecting renal function is not recommended. Administration of bisphosphonates has been associated with abdominal pain (colic), discomfort, and agitation in horses. Clinical signs usually occur shortly after drug administration and may be associated with alterations in intestinal motility. In horses treated with OSPHOS these clinical signs usually began within 2 hours of treatment. Horses should be monitored for at least 2 hours following administration of OSPHOS. Bisphosphonates affect plasma concentrations of some min- erals and electrolytes such as calcium, magnesium and po- tassium, immediately post-treatment, with effects lasting up to several hours. Caution should be used when administering bisphosphonates to horses with conditions affecting mineral or electrolyte homeostasis (e.g. hyperkalemic periodic paralysis, hypocalcemia, etc.). ® The safe use of OSPHOS has not been evaluated in horses less OSPHOS Easily Administered than 4 years of age. The effect of bisphosphonates on the skel- eton of growing horses has not been studied; however, bisphos- phonates inhibit osteoclast activity which impacts bone turnover via intramuscular injection and may affect bone growth. controls the Bisphosphonates should not be used in pregnant or lactating * mares, or mares intended for breeding. The safe use of OSPHOS Well Tolerated has not been evaluated in breeding horses or pregnant or lac- tating mares. Bisphosphonates are incorporated into the bone clinical signs in clinical trials matrix, from where they are gradually released over periods of months to years. The extent of bisphosphonate incorporation into adult bone, and hence, the amount available for release Proven Efficacy* back into the systemic circulation, is directly related to the to- associated tal dose and duration of bisphosphonate use. Bisphosphonates have been shown to cause fetal developmental abnormalities at 6 months post treatment in laboratory animals. The uptake of bisphosphonates into fetal bone may be greater than into maternal bone creating a possible risk for skeletal or other abnormalities in the fetus. Many drugs, with Navicular including bisphosphonates, may be excreted in milk and may be No Reconstitution absorbed by nursing animals. Increased bone fragility has been observed in animals treated Syndrome with bisphosphonates at high doses or for long periods of time. Bisphosphonates inhibit bone resorption and decrease bone turnover which may lead to an inability to repair micro damage within the bone. In humans, atypical femur fractures have been Learn more online reported in patients on long term bisphosphonate therapy; how- ever, a causal relationship has not been established. www.dechra-us.com ADVERSE REACTIONS: The most common adverse reactions reported in the field study were clinical signs of discomfort or www.osphos.com nervousness, colic and/or pawing. Other signs reported were lip licking, yawning, head shaking, injection site swelling, and hives/pruritus. As with all drugs, side effects may occur. In field studies, the most common side effects reported were signs of discomfort or nervousness, colic, and/or pawing. OSPHOS should not be used in pregnant or lactating mares, or mares intended for breeding. Distributed by: Dechra Veterinary Products Use of OSPHOS in patients with conditions affecting renal function or mineral or electrolyte homeostasis is not recommended. 7015 College Boulevard, Suite 525 Overland Park, KS 66211 866-933-2472 Refer to the prescribing information for complete details or visit www.dechra-us.com or call 866.933.2472. CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian. © 2016 Dechra Ltd. OSPHOS is a registered trademark of Dechra Ltd. All rights reserved. * Freedom of Information Summary, Original New Animal Drug Application, NADA 141-427, for OSPHOS. April 28, 2014. NADA 141-427, Approved by FDA Dechra Veterinary Products US and the Dechra D logo are registered trademarks of Dechra Pharmaceuticals PLC. © 2016 Dechra Ltd. equus Fly Predators® vs ® EDITORIAL DIRECTOR Cathy Laws GROUP PUBLISHER David Andrick [email protected] ADVERTISING ASSOCIATE PUBLISHER Shelley Partridge 859-327-7057; [email protected]